Articles On Biotron (ASX:BIT)

Australian shares rose to a two-week high as investors weighed positive overnight leads against the impact of bushfires and the coronavirus on company earnings. The ASX 200 advanced 51 points or 0.7 per cent to 7063, the index’s highest...

Biotron (ASX:BIT) has joined the global search for a coronavirus vaccine by confirming it is evaluating several compounds, including the new novel strain known as 2019-nCoV.

A fresh decade-low for the dollar ended today’s session on a weak note, leaving Australian markets in the red. Despite attempts to climb against the greenback later in the day, the dollar was worth as little as 66.6 US cents this morning...

As the coronavirus death toll overtakes the 2002 SARS outbreak, demand for Holista Colltech’s (HCT) NatShield sanitising spray has risen once again Holista will now ship a further 90,000 units to Kuala Lumpur after the original top-up of 6...

The Biotron Limited (ASX: BIT) share price has been a standout performer on the Australian share market this week. On Friday afternoon the clinical stage biotechnology company’s shares have rocketed higher for a second day in a row. At the...

The S&P/ASX 200 index is on course to end the week deep in the red. In afternoon trade the benchmark index is down 0.6% to 7,007.2 points. Four shares that have not let that hold them back today are listed below. Here’s why they are st...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Global markets continued their rebound today as commodity prices reversed last week’s losses. Overnight, European and American markets had another happy trading session, setting the ASX up for its third straight rise. Our benchmark...

Australia’s S&P/ASX 200 (Index: ^AXJO)(ASX: XJO) and ALL ORDINARIES (Index: ^AXAO) (ASX: XAO) indices finished higher on Thursday. Here’s a short recap of the Australian market: S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) higher 1.05%...

The S&P/ASX 200 index has followed the lead of U.S. markets and is pushing higher again. In afternoon trade the benchmark index is up 0.8% to 7,030.9 points. Four shares that are climbing more than most today are listed below. Here’s w...

Following market speculation in January, Biotron (BIT) has emerged as a potential runner in the race to find the coronavirus cure The Biotech specialist said it has 30 antivirus compounds which show potential in their ability to treat the...

As global authorities race to contain the outbreak of coronavirus, Aussie healthcare stock Biotron (ASX:BIT) thinks it may be able to help. The company’s primary focus is anti-virus medications for HIV and Hepatitis B, via the development o...

Australian clinical stage company Biotron (ASX: BIT) has announced it will commence the evaluation of “several promising compounds” which could target various strains of coronavirus, including the deadly 2019-nCoV creating a global health i...

One of the best performers on the ASX on Thursday has been the Biotron Limited (ASX: BIT) share price. In morning trade the clinical stage biotechnology company’s shares rocketed 28% higher to 10.5 cents. They have since pulled back a touc...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Aussie shares rose for a second day after Chinese stimulus measures helped a global market rebound gather momentum overnight. The ASX 200 briefly regained the 7000 level before paring its gain to 27 points or 0.4 per cent at 6976. At its...

By Tim Boreham, Editor, The New Criterion Stocks that tap the disaster zeitgeist With the stock market off to a galloping start in 2020 – at least before the coranavirus sniffles set in — most investors would have been content with a passiv...

A rebound on Wall Street and the possibility of a surprise rate cut this afternoon helped the share market inch higher despite pressure on resource stocks. The ASX 200 gained momentum after a turgid opening hour, rising 34 points or 0.5...

The Australian share market tumbled 80 points as oil touched its lowest level in a year and Chinese markets re-opened with massive losses. The ASX 200 surrendered its grip on 7,000, falling 1.1 per cent to 6933 by mid-session. At its nad...

Coronavirus scares and bushfire reconstruction play into the stock prices of small caps Biotron and Johns Lyng.

Rising coronavirus fears have ignited demand for Hollister Colltech’s (HTC) NatShield Sanitiser in Kuala Lumpur The company has already sold out of its sanitising spray in Malaysia’s capital To combat rising demand for Natshield, Holista p...

As global markets move cautiously around the spreading Wuhan coronavirus, the ASX managed to recoup a small portion of yesterday’s losses with some tepid gains. The ASX 200 couldn’t get back Wednesday’s all-time highs but managed to add...

Biotech researcher Biotron (BIT) has been in the spotlight this week for a potential coronavirus cure Eagle-eyed investors noticed a late-December U.S. patent application mentioned specific treatments for the virus The company’s shares jum...

Stocks retreated from record highs as strong jobs growth undermined the case for further rate cuts. The ASX 200 fell 41 points or 0.6 per cent to 7092 by mid-session, erasing almost two-thirds of yesterday’s 66-point surge. Early los...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Board member Robert Thomas purchased one million shares in the company yesterday and shares finished up 40%.

Cancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies dip in and out of respiratory diseases all the time. But there are a few ASX-listed stocks that are tackling health issues that still rate as...

Drug development is an extensive process and includes drug discovery & development, pre-clinical and clinical research and FDA approvals, including Post-Market Drug Safety Monitoring. The first and the most essential step of drug devel...

Biotron Limited (ASX: BIT) would be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (‘CROI’), to be held in Boston MA, USA in March 2020. Ever since the company completed the BIT225-009...

Biotron (ASX BIT) has announced it has entered an Option Underwriting Agreement with Gleneagle Securities.

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

In Australia, there are plenty of high-quality health care companies, most of which have delivered excellent returns. Investment in health care stocks is high yielding; however, it does include risks. If undergoing clinical studies fail to...

Australian Health Care is a dynamic sector with a potential to generate significant profits in the least amount of time, something, what investors eye for, while pouring cash in Stocks. In this article we will be digging into four Health Ca...

The Australian benchmark index S&P/ASX200 was trading at 6,499.1, up by 0.09 per cent (as on 4 October 2019, AEST 12:20 PM). In this article, we would discuss four diversified stocks wherein, Great Boulder Resources Limited is from the...

On 1 October 2005, I was only 20 metres away from a large bomb that went off in the heart of Kuta. The 2005 Bali bombings were a series of terrorist attacks across two sites in Jimbaran Bay and in Kuta - 30km away from each other, both in s...

Resources companies have come out on top in ASX small caps over the past 12 months – but now only account for just over 40 per cent of the 100 best performers in the 2019 financial year. Stockhead has compiled a list (see below) of the top...

Australia has a robust health care system, jointly operated by the federal, state and local governments, and is labeled as one of the best in the world. For investors, health care stands among the top few sectors, and is the safest sectors...

Holding huge growth potential, small cap stocks are those companies that are often under-recognised and have a small market capitalisation. Strategies like strategic collaborations or capital infusion give these companies business growth. H...

The micro or small-cap end of the share market is full of shares that will regularly move rapidly higher or lower in the space of just a few days as sentiment swings around the businesses and a lack of liquidity adds to the volatility.  It...

In this piece of writing, we would discuss the three stocks from healthcare sector traded on the ASX. The Australian benchmark index S&P/ASX 200 closed at 6793.4, down by 24.60 points or 0.4% from the previous close, on 26 July 2019. Ov...

The stocks that trade for less than $1 per share and have very low market capitalisation are usually referred to the penny stocks. These stocks are generally associated with small companies and are less liquid. However, penny stocks enable...

Biotron (ASX:BIT), the biotech company that skyrocketed 750 per cent in the space of a week after promising clinical trial results, will host a scientific advisory meeting with “internationally-recognised” HIV-1 experts in the coming weeks....

Australian company Biotron (ASX:BIT) has updated shareholders following the release of positive outcomes from the BIT225-009 phase 2 HIV-1 clinical trial.